Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 19/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL694227 | 1.00 | P2RY12 (0.46) | P2RY12LMNAPOLBSMN1; SMN2 | |
| Acetic Acid SCHEMBL317606 | 0.97 | P2RY12 (0.47) | P2RY12LMNAPOLBSMN1; SMN2 | |
| SCHEMBL956440 | 0.93 | P2RY12 (0.41) | P2RY12 | |
| SCHEMBL956438 | 0.93 | P2RY12 (0.41) | P2RY12 | |
| SCHEMBL317073 | 0.89 | DPP4 (0.44) | P2RY12POLBSMN1; SMN2 | |
| SCHEMBL317074 | 0.89 | DPP4 (0.44) | P2RY12POLBSMN1; SMN2 | |
| SCHEMBL694085 | 0.87 | SMN1; SMN2 (0.47) | P2RY12LMNAPOLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL718574 | 0.86 | SMN1; SMN2 (0.46) | P2RY12LMNAPOLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL718575 | 0.86 | SMN1; SMN2 (0.46) | P2RY12LMNAPOLBSMN1; SMN2 | |
| SCHEMBL1143510 | 0.84 | TSHR (0.40) | P2RY12POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669266-B2 | Quinoline-carboxamide derivatives as P2Y12 antagonists | SANOFI (FR) | 2014-03-11 | — | — | US | disclosed |
| US-8664203-B2 | Thiazole derivatives and their use as P2Y12 receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-03-04 | — | — | US | disclosed |
| US-20130281406-A2 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-24 | — | — | US | disclosed |
| US-8466156-B2 | 2-phenyl-4-cyclopropyl-pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-06-18 | — | — | US | disclosed |
| US-8466156-B2 | 2-phenyl-4-cyclopropyl-pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-06-18 | — | — | US | disclosed |
| US-8466156-B2 | 2-phenyl-4-cyclopropyl-pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-06-18 | — | — | US | disclosed |
| US-8426420-B2 | Heterocyclic pyrazole-carboxamidesas P2Y12 antagonists | SANOFI (FR) | 2013-04-23 | — | — | US | disclosed |
| EP-2238128-B1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFI SA (FR) | 2012-08-22 | — | — | EP | disclosed |
| US-20120053149-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-01 | — | — | US | disclosed |
| EP-2421859-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-02-29 | — | — | EP | disclosed |
| US-20110028484-A1 | 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2011-02-03 | — | — | US | disclosed |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| WO-2010122504-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-10-28 | — | — | WO | disclosed |
| EP-2238128-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-10-13 | — | — | EP | disclosed |
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2148871-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | Sanofi-Aventis (FR) | 2010-02-03 | — | — | EP | disclosed |
| WO-2009125365-A1 | 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009125365-A1 | 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-15 | — | — | WO | disclosed |
| WO-2009080226-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFIS-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100135999-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | P2RY12, P2RY1, P2RY2 | P2RY12 1/4885LMNA 977/4885POLB 1874/4885 |
| US-20110021537-A1 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS | P2RY1, P2RY12, P2RY11 | P2RY12 2/4885LMNA 1671/4885POLB 2236/4885 |
| US-20120053149-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | P2RY12, P2RY1, P2RY2 | P2RY12 1/4885LMNA 3423/4885POLB 4348/4885 |
| US-20130281406-A2 | THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS | P2RY12, P2RY1, P2RY2 | P2RY12 1/4885LMNA 3566/4885POLB 4457/4885 |
| US-20110028484-A1 | 2-PHENYL-4-CYCLOPROPYL-PYRIMIDINE DERIVATIVES | P2RY12, P2RY13, P2RY4 | P2RY12 1/4885LMNA 3905/4885POLB 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.